Do Resource Utilization and Clinical Measures Still Vary Across Dialysis Chains After Controlling for the Local Practices of Facilities and Physicians?
Authors:
- Richard A. HirthRHRichard A. Hirth
- Marc N. TurenneMTMarc N. Turenne
- John R. C. WheelerJWJohn R. C. Wheeler
- Yu MaYMYu Ma
- Joseph M. MessanaJMJoseph M. Messana
- 1 August 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 48 (8) , 726-732
Abstract
Because of adverse survival effects, anemia management and financial incentives to increase doses of erythropoiesis-stimulating agents (ESAs) have been controversial. Prior studies showed more aggressive anemia management in dialysis facilities owned by for-profit chains, but have been criticized for not accounting for practices of individual physicians and facilities. To improve understanding of how dialysis practices and resource utilization are influenced by physicians, facilities, and chains. Mixed models with chain fixed effects and facility and physician random effects. Medicare hemodialysis patients in 2004. A total of 234,158 patients, 3995 facilities, 4838 physicians, and 7 chain classifications were included. Spending per session for dialysis-related services billed separately from the dialysis treatment and for ESAs. Achievement of hematocrit (HCT) and urea reduction ratio (URR) targets. Of the 4 largest for-profit chains, 3 had higher resource use than independents, with differences up to $17.92 higher ESA/session. Utilization was positively associated with achieving target HCT. Despite incurring lower costs, patients treated by a large nonprofit chain were as likely as patients of independents to achieve the HCT target. The largest chains were more likely than independents to achieve the URR target. Substantial variation occurred across physicians and facilities, and adjustment for chain only modestly decreased this variation. Chains' methods of influencing practices were not directly observed. Chains appear to have the ability to implement protocols that shift practices, but not the ability to substantially reduce local variation. Assertions that chain effects found by earlier studies were spurious are not supported.Keywords
This publication has 21 references indexed in Scilit:
- Association of Quarterly Average Achieved Hematocrit With Mortality in Dialysis Patients: A Time-Dependent Comorbidity-Adjusted ModelAmerican Journal of Kidney Diseases, 2009
- Continued Challenges with the Use of Erythropoiesis‐Stimulating Agents in Patients with Cancer: Perspectives and Issues on Policy‐Guided Health CarePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: An OverviewAmerican Journal of Kidney Diseases, 2007
- Use of Epoetin in Chronic Renal FailureJAMA, 2007
- Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving HemodialysisJAMA, 2007
- EPO Adjustments in Patients With Elevated Hemoglobin Levels: Provider Practice Patterns Compared With Recommended Practice GuidelinesAmerican Journal of Kidney Diseases, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis PatientsJournal of the American Society of Nephrology, 2006
- Epoetin requirements predict mortality in hemodialysis patientsAmerican Journal of Kidney Diseases, 2004
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998